{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:40:48Z","timestamp":1780468848275,"version":"3.54.1"},"reference-count":27,"publisher":"European Respiratory Society (ERS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2013,10,6]]},"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:p>We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic obstructive pulmonary disease.<\/jats:p>\n                  <jats:p>\n                    In this multicentre, blinded, double-dummy, three-period crossover study, 247 patients were randomised to once-daily QVA149 110\/50 \u03bcg, placebo or tiotropium 18 \u03bcg. Superiority of QVA149\n                    <jats:italic>versus<\/jats:italic>\n                    placebo (primary objective) and tiotropium (secondary objective) was assessed for improvement in dyspnoea\n                    <jats:italic>via<\/jats:italic>\n                    the self-administered computerised (SAC) version of the Baseline and Transition Dyspnoea Index after 6 weeks. Secondary end-points included lung function, rescue medication use and safety.\n                  <\/jats:p>\n                  <jats:p>\n                    After 6 weeks, the SAC Transition Dyspnoea Index total score was significantly higher with QVA149\n                    <jats:italic>versus<\/jats:italic>\n                    placebo (least squares mean (LSM) treatment difference 1.37, p&lt;0.001) and tiotropium (LSM treatment difference 0.49, p=0.021). QVA149 provided significant improvements in lung function, with higher forced expiratory volume in 1 s area under the curve from 0\u20134 h post-dose\n                    <jats:italic>versus<\/jats:italic>\n                    placebo and tiotropium at day 1 and week 6 (all p&lt;0.001). Rescue medication use was significantly lower with QVA149\n                    <jats:italic>versus<\/jats:italic>\n                    placebo (p&lt;0.001) and tiotropium (p=0.002). All treatments were well tolerated.\n                  <\/jats:p>\n                  <jats:p>\n                    Once-daily QVA149 provided superior improvements in patient-reported dyspnoea and lung function\n                    <jats:italic>versus<\/jats:italic>\n                    placebo and tiotropium. These benefits were associated with improvements in other symptoms and reduced use of rescue medication.\n                  <\/jats:p>","DOI":"10.1183\/09031936.00124013","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T04:00:38Z","timestamp":1383278438000},"page":"1599-1609","source":"Crossref","is-referenced-by-count":118,"title":["Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study"],"prefix":"10.1183","volume":"43","author":[{"given":"Donald A.","family":"Mahler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Decramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"D'Urzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.T.","family":"Alagappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1roly","family":"Kulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"key":"2024102022103938000_43.6.1599.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200703-456SO"},{"key":"2024102022103938000_43.6.1599.2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2013 Update. www.goldcopd.com ."},{"key":"2024102022103938000_43.6.1599.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00099306"},{"key":"2024102022103938000_43.6.1599.4","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-120030829"},{"key":"2024102022103938000_43.6.1599.5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0934"},{"key":"2024102022103938000_43.6.1599.6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0703"},{"key":"2024102022103938000_43.6.1599.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.12.019"},{"key":"2024102022103938000_43.6.1599.8","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201140"},{"issue":"Suppl. 50","key":"2024102022103938000_43.6.1599.9","first-page":"429s","article-title":"Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together","volume":"28","author":"Vogelmeier","year":"2006","journal-title":"Eur Respir J"},{"key":"2024102022103938000_43.6.1599.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00140404"},{"key":"2024102022103938000_43.6.1599.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.3.509"},{"key":"2024102022103938000_43.6.1599.12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/COPD.S32451","article-title":"Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial","volume":"7","author":"Beeh","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102022103938000_43.6.1599.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00191810"},{"key":"2024102022103938000_43.6.1599.14","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-156"},{"key":"2024102022103938000_43.6.1599.15","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.125435"},{"key":"2024102022103938000_43.6.1599.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200910-1500OC"},{"key":"2024102022103938000_43.6.1599.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00040712"},{"key":"2024102022103938000_43.6.1599.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.02.008"},{"key":"2024102022103938000_43.6.1599.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00045810"},{"key":"2024102022103938000_43.6.1599.20","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00200212"},{"key":"2024102022103938000_43.6.1599.21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(12)70052-8"},{"key":"2024102022103938000_43.6.1599.22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70052-3"},{"key":"2024102022103938000_43.6.1599.23","unstructured":"Global Initiative for Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2009 Update. www.goldcopd.com ."},{"key":"2024102022103938000_43.6.1599.24","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/j.jval.2012.03.338","article-title":"Acceptability of the self-administered computerized (SAC) versions of the baseline\/transition dyspnea indexes (BDI\/TDI) for patients with COPD from seven countries","volume":"15","author":"Brunel","year":"2012","journal-title":"Value Health"},{"key":"2024102022103938000_43.6.1599.25","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.7.581"},{"key":"2024102022103938000_43.6.1599.26","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050666"},{"key":"2024102022103938000_43.6.1599.27","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200053377"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00124013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:46:15Z","timestamp":1740361575000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00124013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,5,31]]},"published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1183\/09031936.00124013"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00124013","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718163311.793532757","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}